Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibition in Preclinical Arthritis
2024-514026-23-00Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- May 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Development of arthritis at week 48. Started May 2024; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-514026-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514026-23-00.